Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) EBITDA (2019 - 2025)

Historic EBITDA for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to -$174.5 million.

  • Avidity Biosciences' EBITDA fell 13948.9% to -$174.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$555.1 million, marking a year-over-year decrease of 10445.73%. This contributed to the annual value of -$319.5 million for FY2024, which is 5259.29% down from last year.
  • Per Avidity Biosciences' latest filing, its EBITDA stood at -$174.5 million for Q3 2025, which was down 13948.9% from -$158.3 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' EBITDA ranged from a high of -$23.8 million in Q1 2021 and a low of -$174.5 million during Q3 2025
  • Its 5-year average for EBITDA is -$67.0 million, with a median of -$51.2 million in 2023.
  • Its EBITDA has fluctuated over the past 5 years, first tumbled by 29181.59% in 2021, then plummeted by 324.12% in 2023.
  • Quarter analysis of 5 years shows Avidity Biosciences' EBITDA stood at -$38.7 million in 2021, then dropped by 28.36% to -$49.7 million in 2022, then fell by 17.57% to -$58.4 million in 2023, then crashed by 82.16% to -$106.5 million in 2024, then plummeted by 63.87% to -$174.5 million in 2025.
  • Its last three reported values are -$174.5 million in Q3 2025, -$158.3 million for Q2 2025, and -$115.9 million during Q1 2025.